ArticleBMC cancer2025
Analysis of the predictive effect of gut microbiota changes on the occurrence of chemotherapy resistance in pancreatic cancer patients based on nomogram prediction models.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding the cancer microbiome: multi-omics, AI, and translational opportunities.Genome biology · 2026Review
- 7. Developing high-performance prediction models for medical outcomes.Journal of postgraduate medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInvestigate gut microbiota's role in chemotherapy resistance development among pancreatic cancer patients and evaluate a nomogram prediction model.
methods510 pancreatic cancer patients who received chemotherapy in our hospital from January 2023 to December 2024 were randomly divided into training set (n = 357) and validation set (n = 153). Risk factors for chemotherapy resistance in pancreatic cancer were screened through multiple logistic regression analysis, and a Nomogram model was constructed. The predictive efficacy of the model was evaluated by drawing the receiver operating characteristic curve and calibration curve, and was verified in the validation set. The clinical application value of the model was evaluated using decision curve analysis.
resultsThe incidence of resistance in the training set was 64.99% (232/357), and that in the validation set was 65.36% (100/153). Multiple logistic regression analysis showed that Escherichia coli, Enterococcus faecalis, and Fusobacterium nucleatum were independent risk factors affecting the occurrence of chemotherapy resistance in pancreatic cancer patients (P < 0.05), while Akkermansia and Bifidobacterium were independent protective factors affecting the occurrence of chemotherapy resistance in pancreatic cancer patients (all P < 0.05). The C-indexes of the constructed Nomogram model in the training set and the validation set were 0.767 and 0.762 respectively. The areas under the curve (AUC) were 0.767 (95% CI: 0.708-0.827) and 0.762 (95% CI: 0.669-0.854) respectively. The sensitivity and specificity were 0.455, 0.865 and 0.511, 0.873 respectively.
conclusionThe Nomogram prediction model constructed based on gut microbiota change indicators has a high predictive efficacy for the occurrence of chemotherapy resistance in pancreatic cancer patients, providing a basis for clinical early screening and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.